SSY Group Shines at CPHI China 2026 – the 24th World Pharmaceutical Raw Materials Exhibition

Gathering global pharmaceutical strengths to jointly unlock new industrial growth opportunities. Held from June 16 to 18 at Shanghai New International Expo Centre, CPHI China 2026 (the 24th World Pharmaceutical Raw Materials Exhibition) welcomed a grand opening. SSY Group showcased its flagship products including finished preparations, APIs and pharmaceutical packaging materials, fully demonstrating its core strengths and technological innovation advantages built on an integrated full industrial chain covering APIs, finished preparations and medical packaging materials.

As a vital driving force and innovation hub for the transformation and upgrading of the pharmaceutical sector, CPHI China, together with the concurrent PMEC China 2026 (the 19th World Pharmaceutical Machinery, Packaging Equipment & Materials Exhibition China), has built a complete industrial ecosystem. Through cutting-edge technology displays, in-depth industry exchanges and efficient resource matchmaking, the expo delivers valuable commercial and strategic opportunities for enterprises and continuously fuels high-quality development of the pharmaceutical industry.

Ranked among China’s Top 100 Pharmaceutical Manufacturers with years of profound engagement in the medical industry, SSY Group boasts mature R&D and production systems as well as comprehensive industrial layout, forming a diversified portfolio of premium pharmaceutical products. The full range of competitive products displayed at this exhibition stands as a concentrated embodiment of the Group’s integrated industrial competitiveness across the whole value chain.

The exhibition hall bustled with crowds brimming with potential cooperation opportunities. The elaborately built SSY Group booth drew constant streams of merchants and professional visitors, maintaining robust foot traffic throughout the show.

Core API products including caffeine, azithromycin, moxifloxacin and aminophylline stood out prominently, while promising varieties such as epalrestat and trelagliptin succinate also garnered extensive attention. Yuan Benyuan, General Manager of the Group’s API International Trade Center, stated that clients, especially overseas buyers, pay close attention to the Group’s eco-friendly intelligent manufacturing systems, advanced production technologies and authoritative international certifications including EU CEP. Numerous merchants spoke highly of the Group’s high value-added APIs during on-site communications.

Targeting international demand for finished pharmaceutical products, the Group also promoted a lineup of key preparations such as paracetamol mannitol injection, medium-and-long-chain fat emulsion injection of propofol, peritoneal dialysis solution and urapidil sustained-release capsules. Leveraging its integrated advantages across APIs, preparations and pharmaceutical packaging plus a growing portfolio of international certifications, these finished products won wide favor among global attendees. A person in charge of the Group’s finished drug export business noted that the Group will further internationalize its product pipeline to facilitate more high-quality pharmaceutical products going global.

In the pharmaceutical packaging pavilion, the Group’s subsidiary Bosheng Medical Packaging operated an independent booth echoing the main SSY stand, jointly highlighting the Group’s full-chain advantages spanning APIs, finished preparations and high-end medical packaging materials. As the core innovation platform for the Group’s premium packaging segment, Bosheng Medical Packaging’s eye-catching booth fully exhibited the technical prowess and industry responsibility of a leading domestic pharmaceutical packaging manufacturer.

From the opening day, Bosheng’s booth saw an endless stream of consulting buyers. A Bosheng executive introduced: “We brought a full series of high-end products this time, including multi-layer co-extrusion films, medical hoses, biological films, coated rubber stoppers, prefillable syringe plungers and pen injector plungers. Many core items hold international certifications, and we have reached preliminary cooperation intentions with multiple clients.”

In recent years, Bosheng Medical Packaging has achieved remarkable progress in industry standard formulation and smart manufacturing. It participated in drafting relevant standards for the 2025 edition of the Chinese Pharmacopoeia, and its “5G Smart Factory for Multi-layer Co-extrusion Biological Films” was shortlisted in the MIIT National 5G Factory Directory, showcasing fruitful achievements in the digital and intelligent transformation of modern pharmaceutical packaging enterprises.

Guided by technological innovation, the Group adheres to its core strategies of innovation-driven development, quality prioritization and smooth domestic-international dual circulation. It keeps boosting R&D investment, upgrading production technologies and product lines, and refining its integrated full industrial chain layout covering APIs, finished preparations and packaging materials to advance coordinated high-quality development of upstream and downstream sectors. Up to now, the Group has obtained approval certificates for 102 API varieties, with a total of 188 product varieties and 250 specifications passing or being deemed to pass the Consistency Evaluation of Quality and Efficacy of Generic Drugs.

Standing at a new starting point for future development, senior management of the Group remarked that SSY will further deepen its presence in the biomedicine sector, take technological innovation as the driving force and high-quality products as the foundation to actively embrace global markets and expand industrial exchanges and partnerships worldwide. The Group will accelerate its transformation into an innovation-oriented pharmaceutical enterprise, prioritize the layout of innovative product pipelines, strive to develop more high-quality “Chinese-made medicines”, and contribute robust strength from SSY to the advancement of global medical and healthcare undertakings.